Critical role of cell competition in gliomagenesis

Read full text
Authors: Ying Jiang, Ryuhjin Ahn, Arthur Huang, Phillippe P. Gonzalez, Jungeun Kim, Guoxin Zhang, Zihao Liu, Zhenqiang He, Lindsey Anne Dudley, Kunal S. Patel, Godfrey A. Dzhivhuho, Sam Crowl
+14 more Piotr Przanowski, Luisa Quesada Camacho, Sijie Hao, Jianhao Zeng, Simon Hippenmeyer, Mohammad Fallahi‐Sichani, Kevin A. Janes, Kristen M. Naegle, Marie‐Louise Hammarskjöld, Steven A. Goldman, Harley I. Kornblum, MaoJin YAO, Forest M. White, Hui Zong
Cited by: 0
References: 121

Abstract

ABSTRACT Malignant glioma is incurable. Using a mouse genetic mosaic system to generate sporadic Trp53,Nf1 -null OPCs, we previously identified oligodendrocyte precursor cell (OPC) as a cell-of-origin of glioma. Here, we report that pre-malignant Trp53,Nf1 -null OPCs outcompete wildtype counterparts during their expansion. Blocking competition by mutating/strengthening wildtype OPCs impeded both pre-malignant progression and malignant expansion of glioma. “In-tissue” phosphoproteomic profiling revealed an enrichment of phosphopeptides related to RNA splicing and protein translation at the peak of cell competition, suggesting that competitiveness may stem from unique protein species. Among candidates was mTORC1, whose pharmacological inhibition or genetic disruption resulted in a loss of competitiveness in our mouse model. Finally, analysis of patient biopsies and interrogating the role of individual gliomagenic mutations in OPC competition supported its relevance in human gliomas. Together, these findings identified the driving role of competitive interactions among OPCs in gliomagenesis, and suggest unconventional therapeutic strategies to target this process.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Cancer-related Molecular Pathways PI3K/AKT/mTOR signaling in cancer

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
16 January 2026
Language
EN
Document type
Preprint